Hymenoptera Venom Allergy
Conditions
Keywords
Hymenoptera venom allergy, Dendritic cells (DC)
Brief summary
Dendritic cells (DC) play a key role in the pathogenesis of allergic diseases. The regulation of blood dendritic cells in patients with hymenoptera venom allergy before and during immune therapy is unknown.
Interventions
BIOLOGICALHymenoptera venom
Patients are treated with hymenoptera (bee or wasp) venom using subcutaneous injections. The initiation of immune therapy consists of a 52-hour-period in which patients are treated with increasing doses of hymenoptera venom. Afterwards, patients are treated with monthly subcutaneous injections with a fixed dose of hymenoptera venom. Blood will be collected directly before and 1 hour after initiation of immune therapy and after 12 months of immune therapy (directly before the next subcutaneous injection of hymenoptera venom).
Sponsors
University of Rostock
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
BASIC_SCIENCE
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
16 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* Patients with diagnosed hymenoptera venom allergy * No previous treatments for hymenoptera venom allergy
Exclusion criteria
* Treatment with immunosuppressive agents * Any malignant disease * Infections within 1 week prior to the initiation of the treatment
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Number of myeloid DC and plasmacytoid DC in peripheral blood | Directly before, 1 hour after, and 12 months after initiation of immune therapy |
Secondary
| Measure | Time frame |
|---|---|
| Surface molecule expression on myeloid DC and plasmacytoid DC | Directly before, 1 hour after, and 12 months after initiation of immune therapy |
Countries
Germany
Outcome results
None listed